NASDAQ:TARS Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis $73.16 +0.94 (+1.30%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$74.32 +1.16 (+1.58%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Tarsus Pharmaceuticals Stock (NASDAQ:TARS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tarsus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$71.20▼$73.9350-Day Range$61.11▼$90.7852-Week Range$53.89▼$91.53Volume481,752 shsAverage Volume747,312 shsMarket Capitalization$3.21 billionP/E RatioN/ADividend YieldN/APrice Target$100.86Consensus RatingModerate Buy Company Overview Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company concentrates on areas of significant unmet need in ophthalmology and aims to address conditions that can affect ocular health, comfort and vision. Tarsus’ primary product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis. The condition is associated with an infestation of Demodex mites and can cause eyelid inflammation, irritation and other ocular symptoms. XDEMVY is the first FDA-approved treatment specifically indicated for Demodex blepharitis. Founded in 2016 and headquartered in Irvine, California, Tarsus markets XDEMVY in the United States and continues to develop additional ophthalmic therapies. The company is led by President and Chief Executive Officer Bobak R. Azam, M.D., who has experience in the biotechnology and pharmaceutical industries.AI Generated. May Contain Errors. Read More Tarsus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreTARS MarketRank™: Tarsus Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 195th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialTarsus Pharmaceuticals has a consensus price target of $100.86, representing about 37.9% upside from its current price of $73.16.Amount of Analyst CoverageTarsus Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tarsus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($4.25) to $0.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -67.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -67.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 9.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tarsus Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.31% of the float of Tarsus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 8.29.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently decreased by 0.93%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.51 News SentimentTarsus Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Tarsus Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest1 people have searched for TARS on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,004,227.00 in company stock.Percentage Held by Insiders9.64% of the stock of Tarsus Pharmaceuticals is held by insiders.Percentage Held by Institutions90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tarsus Pharmaceuticals' insider trading history. Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARS Stock News HeadlinesTarsus Pharmaceuticals (NASDAQ:TARS) Cut to Strong Sell at Zacks ResearchOctober 8 at 6:06 AM | americanbankingnews.comTarsus Pharmaceuticals: XDEMVY Now Pays The Bills, And The Retina Deals Work Like OptionsOctober 6, 2026 | seekingalpha.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock Now Rated "Moderate Buy" by Wall Street BrokeragesOctober 5, 2026 | americanbankingnews.comHead-To-Head Survey: Tarsus Pharmaceuticals (NASDAQ:TARS) & Astrazeneca (NYSE:AZN)October 4, 2026 | americanbankingnews.comTarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry ...September 29, 2026 | markets.businessinsider.comTarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual MeetingSeptember 29, 2026 | globenewswire.comInsider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $905,600.00 in StockSeptember 10, 2026 | insidertrades.comSee More Headlines TARS Stock Analysis - Frequently Asked Questions How have TARS shares performed this year? Tarsus Pharmaceuticals' stock was trading at $81.88 on January 1st, 2026. Since then, TARS shares have decreased by 10.6% and is now trading at $73.16. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.24. The business earned $173.91 million during the quarter, compared to analyst estimates of $169.65 million. Tarsus Pharmaceuticals had a negative net margin of 7.67% and a negative trailing twelve-month return on equity of 13.53%. Read the conference call transcript. When did Tarsus Pharmaceuticals IPO? Tarsus Pharmaceuticals (TARS) raised $88 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 5,500,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Who are Tarsus Pharmaceuticals' major shareholders? Tarsus Pharmaceuticals' top institutional investors include Farther Finance Advisors LLC. Insiders that own company stock include Bobak R Azamian, William J Phd Link, Seshadri Neervannan, Bryan Wahl, Jeffrey S Farrow, Aziz Mottiwala, Dianne C Whitfield, Andrew D Goldberg, Elizabeth Yeu Lin, Jose M Trevejo and Katherine Goodrich. View institutional ownership trends. How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tarsus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tarsus Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings8/06/2026Today10/10/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TARS's financial health is in the Green zone, according to TradeSmith. TARS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TARS CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees370Year Founded2017Price Target and Rating Average Price Target for Tarsus Pharmaceuticals$100.86 High Price Target$116.00 Low Price Target$88.00 Potential Upside/Downside+37.9%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.42 million Net Margins-7.67% Pretax Margin-6.49% Return on Equity-13.53% Return on Assets-8.12% Debt Debt-to-Equity Ratio0.21 Current Ratio3.20 Quick Ratio3.17 Sales & Book Value Annual Sales$451.36 million Price / Sales7.11 Cash FlowN/A Price / Cash FlowN/A Book Value$8.09 per share Price / Book9.04Miscellaneous Outstanding Shares43,880,000Free Float39,653,000Market Cap$3.21 billion OptionableOptionable Beta0.44 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TARS) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTech expert smashes iPhone with golf clubTwenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...Stansberry Research | SponsoredElon’s Hiding a Potential $20 Trillion Monster Inside TeslaElon Musk says there is a product inside Tesla's factories he calls the biggest ever made, ten times bigger th...StocksToTrade | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARS Stock Alerts